Immune-based therapies for childhood cancer. (Q38263108)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Immune-based therapies for childhood cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Crystal L Mackall

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Melinda S Merchant

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Terry J Fry

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

English

0 references

publication date

28 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

693-703

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

Declining childhood and adolescent cancer mortality

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Use of NK cell activity in cure by transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Natural killer cells in the treatment of high-risk acute leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Cytotoxicity of activated natural killer cells against pediatric solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Activating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

The future role of monoclonal antibody therapy in childhood acute leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Immunotoxins for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Advances in the treatment of hematologic malignancies using immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Antibody-drug conjugates in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Mobilizing and evaluating anticancer T cells: pitfalls and solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Adoptive immunotherapy for cancer: building on success

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Successful treatment of melanoma brain metastases with adoptive cell therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Ipilimumab and its toxicities: a multidisciplinary approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Current concepts in the diagnosis and management of cytokine release syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Will post-transplantation cell therapies for pediatric patients become standard of care?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Donor selection for KIR B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Chimeric antigen receptor T cells for sustained remissions in leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.177

Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25348789

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25348789

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma patients refractory to chemotherapy: a phase II trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25348789

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2014.177

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

PubMed publication ID

25348789

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25348789%20AND%20SRC:MED&resulttype=core&format=json